Wang Keyan, Sun Jicheng, Zhao Haoran, Wang Fangruyue, Zhang Xiaoyu, Zhao Xiaoqing, Li Zongjun, Zhang Ling, Ren Hui, Guo Baofeng
Department of Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, People's Republic of China.
Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, 130021, People's Republic of China.
Int J Nanomedicine. 2025 Aug 4;20:9597-9620. doi: 10.2147/IJN.S531451. eCollection 2025.
Glioblastoma is the most aggressive and lethal primary brain tumor in adults, with current treatment options offering only limited improvement in patient survival. Despite the advancement of modalities such as immunotherapy, targeted therapy, gene therapy, focused ultrasound, and tumor-treating fields, therapeutic efficacy remains unsatisfactory due to challenges such as the blood-brain barrier, tumor heterogeneity, and treatment resistance. Nanotechnology has emerged as a promising platform to enhance the delivery, specificity, and combinatorial potential of these therapies. By enabling precise and multifunctional delivery of therapeutic agents, nanoscale systems hold the potential to overcome critical biological and pharmacological barriers in glioblastoma treatment. This review provides an overview of recent progress in nanomedicine-based strategies for glioblastoma, critically examines the key challenges that limit their clinical translation, and highlights innovative approaches designed to improve therapeutic outcomes. Future perspectives on how nanotechnology may reshape the landscape of brain tumor treatment are also discussed.
胶质母细胞瘤是成人中最具侵袭性和致命性的原发性脑肿瘤，目前的治疗方案仅能有限地提高患者生存率。尽管免疫疗法、靶向疗法、基因疗法、聚焦超声和肿瘤治疗电场等治疗方式取得了进展，但由于血脑屏障、肿瘤异质性和治疗抗性等挑战，治疗效果仍不尽人意。纳米技术已成为一个有前景的平台，可增强这些疗法的递送、特异性和联合应用潜力。通过实现治疗剂的精确和多功能递送，纳米级系统有潜力克服胶质母细胞瘤治疗中的关键生物学和药理学障碍。本综述概述了基于纳米医学的胶质母细胞瘤治疗策略的最新进展，批判性地审视了限制其临床转化的关键挑战，并强调了旨在改善治疗结果的创新方法。还讨论了纳米技术如何重塑脑肿瘤治疗格局的未来展望。
